Biogen (BIIB) to acquire Apellis Pharma (APLS) for USD 41/shr cash plus CVR, Bloomberg reports

Biogen's decision to acquire Apellis Pharma at USD 41 per share, plus a contingent value right (CVR), suggests a strategic move into a promising sector of biotechnology.

Newsquawk StaffPublished On the live feed at 7 more headlines followed before this page went public
Newsquawk headlinesUTC

AT&T (T) launches OneConnect; AT&T reiterates all 2026 and multi-year financial guidance and capital return plans provided with its fourth-quarter 2025 earnings report

Lilly (LLY) to acquire Centessa Pharmaceuticals (CNTA) to advance treatments for sleep-wake disorders; Will pay USD 38/shr in cash plus potential USD 9.00/shr in future milestones; total potential consideration up to USD 47/shr

Biogen (BIIB) to acquire Apellis Pharma (APLS) for USD 41/shr cash plus CVR, Bloomberg reports

[MARKET UPDATE] Pressure seen in fixed income and European/US equity futures as energy climbs ever closer to overnight highs

McCormick & Company Incorporated (MKC) Q1 2026 (USD): EPS 0.66 (exp. 0.60), Revenue 1.87bln (exp. 1.79bln), Current FY EPS 3.05-3.13 (exp. 3.09)

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
Context

This acquisition could be viewed as accretive, signaling confidence in Apellis' pipeline and potential synergies, while also creating ripple effects in the biotech and pharmaceutical sectors, influencing investor sentiment and valuation benchmarks.

Related headlines

The whole workspace, free to try.

Try it free